Skip to content
Triptolide attenuates irritable bowel syndrome via inhibiting ODC1 | BMC Gastroenterology
Colomier E, Algera J, Melchior C. Pharmacological therapies and their clinical targets in irritable bowel syndrome with Diarrhea. Front Pharmacol. 2020;11:629026.
Google Scholar
Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol. 2017;23(36):6593–627.
Google Scholar
Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345–9.
Google Scholar
Eslampour E, Ghanadi K, Aghamohammadi V, Kazemi AM, Mohammadi R, Vahid F, Abbasnezhad A. Association between dietary inflammatory index (DII) and risk of irritable bowel syndrome: a case-control study. Nutr J. 2021;20(1):60.
Google Scholar
Wang Y, Wang B, Yang X. The study of Cellular mechanism of Triptolide in the treatment of Cancer, Bone loss and Cardiovascular Disease and Triptolide’s toxicity. Curr Stem Cell Res Therapy. 2020;15(1):18–23.
Google Scholar
Jiang X, Cao G, Gao G, Wang W, Zhao J, Gao C. Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12. J Cell Physiol. 2021;236(1):193–204.
Google Scholar
Yang J, Tang X, Ke X, Dai Y, Shi J. Triptolide suppresses NF-κB-Mediated inflammatory responses and activates expression of Nrf2-Mediated antioxidant genes to Alleviate Caerulein-Induced Acute Pancreatitis. Int J Mol Sci 2022, 23(3).
Tao Q, Wang B, Zheng Y, Li G, Ren J. Triptolide ameliorates colonic fibrosis in an experimental rat model. Mol Med Rep. 2015;12(2):1891–7.
Google Scholar
Wei X, Gong J, Zhu J, Niu L, Zhu W, Li N, Li J. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis. Int Immunopharmacol. 2008;8(13–14):1808–12.
Google Scholar
Fu J, Zang Y, Zhou Y, Chen C, Shao S, Shi G, Wu L, Zhu G, Sun T, Zhang D, et al. Exploring a novel triptolide derivative possess anti-colitis effect via regulating T cell differentiation. Int Immunopharmacol. 2021;94:107472.
Google Scholar
Tang B, Zhu J, Zhang B, Wu F, Wang Y, Weng Q, Fang S, Zheng L, Yang Y, Qiu R, et al. Therapeutic potential of Triptolide as an anti-inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis. Front Immunol. 2020;11:592084.
Google Scholar
Downs IA, Aroniadis OC, Kelly L, Brandt LJ. Postinfection Irritable Bowel Syndrome: the links between gastroenteritis, inflammation, the Microbiome, and Functional Disease. J Clin Gastroenterol. 2017;51(10):869–77.
Google Scholar
Xu Y, Cui SY, Ma Q, Shi J, Yu Y, Li JX, Zheng L, Zhang Y, Si JM, Yu YC. Trans-resveratrol ameliorates Stress-Induced Irritable Bowel Syndrome-Like Behaviors by Regulation of Brain-Gut Axis. Front Pharmacol. 2018;9:631.
Google Scholar
Peng V, Cao S, Trsan T, Bando JK, Avila-Pacheco J, Cleveland JL, Clish C, Xavier RJ, Colonna M. Ornithine decarboxylase supports ILC3 responses in infectious and autoimmune colitis through positive regulation of IL-22 transcription. Proc Natl Acad Sci USA. 2022;119(45):e2214900119.
Google Scholar
Singh K, Coburn LA, Asim M, Barry DP, Allaman MM, Shi C, Washington MK, Luis PB, Schneider C, Delgado AG, et al. Ornithine Decarboxylase in Macrophages exacerbates colitis and promotes Colitis-Associated Colon carcinogenesis by impairing M1 Immune responses. Cancer Res. 2018;78(15):4303–15.
Google Scholar
Kerckhove N, Scanzi J, Pereira B, Ardid D, Dapoigny M. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome – IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial. BMJ open. 2017;7(7):e015380.
Google Scholar
Beatty JK, Bhargava A, Buret AG. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol. 2014;20(14):3976–85.
Google Scholar
Hu X, Dong Y, Jin X, Zhang C, Zhang T, Zhao J, Shi J, Li J. The novel and potent anti-depressive action of triptolide and its influences on hippocampal neuroinflammation in a rat model of depression comorbidity of chronic pain. Brain Behav Immun. 2017;64:180–94.
Google Scholar
Wang W, Mei XP, Chen L, Tang J, Li JL, Wu SX, Xu LX, Li YQ. Triptolide prevents and attenuates neuropathic pain via inhibiting central immune response. Pain Physician. 2012;15(6):E995–1006.
Google Scholar
Zou N, Lv H, Li J, Yang N, Xue H, Zhu J, Qian J. Changes in brain G proteins and colonic sympathetic neural signaling in chronic-acute combined stress rat model of irritable bowel syndrome (IBS). Translational research: the journal of laboratory and clinical medicine. 2008;152(6):283–9.
Google Scholar
Yu Y, Wu S, Li J, Wang R, Xie X, Yu X, Pan J, Xu Y, Zheng L. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis. 2015;30(1):47–55.
Google Scholar
Schneider T, Popik P. Attenuation of estrous cycle-dependent marble burying in female rats by acute treatment with progesterone and antidepressants. Psychoneuroendocrinology. 2007;32(6):651–9.
Google Scholar
Barone FC, Deegan JF, Price WJ, Fowler PJ, Fondacaro JD, Ormsbee HS. 3rd: cold-restraint stress increases rat fecal pellet output and colonic transit. Am J Physiol. 1990;258(3 Pt 1):G329–337.
Google Scholar
Yang JM, Xian YF, Ip PS, Wu JC, Lao L, Fong HH, Sung JJ, Berman B, Yeung JH, Che CT. Schisandra chinensis reverses visceral hypersensitivity in a neonatal-maternal separated rat model. Phytomedicine: Int J phytotherapy phytopharmacology. 2012;19(5):402–8.
Google Scholar
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association. 2012;10(7):712–721e714.
Google Scholar
Rivkin A, Rybalov S. Update on the management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline. Pharmacotherapy. 2016;36(3):300–16.
Google Scholar
Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229–39. quiz 1240.
Google Scholar
Meng M, Bai C, Wan B, Zhao L, Li Z, Li D, Zhang S. A Network Pharmacology-Based study on irritable Bowel Syndrome Prevention and Treatment utilizing Shenling Baizhu Powder. Biomed Res Int. 2021;2021:4579850.
Google Scholar
Zhen Z, Xia L, You H, Jingwei Z, Shasha Y, Xinyi W, Wenjing L, Xin Z, Chaomei F. An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong pill for treating diarrhea-predominant irritable bowel syndrome. Front Pharmacol. 2021;12:746923.
Google Scholar
Hinterdobler J, Schunkert H, Kessler T, Sager HB. Impact of Acute and chronic psychosocial stress on vascular inflammation. Antioxidants & redox signaling; 2021.
Heidari R, Niknahad H, Sadeghi A, Mohammadi H, Ghanbarinejad V, Ommati MM, Hosseini A, Azarpira N, Khodaei F, Farshad O, et al. Betaine treatment protects liver through regulating mitochondrial function and counteracting oxidative stress in acute and chronic animal models of hepatic injury. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2018;103:75–86.
Google Scholar
Farah VM, Joaquim LF, Bernatova I, Morris M. Acute and chronic stress influence blood pressure variability in mice. Physiol Behav. 2004;83(1):135–42.
Google Scholar
Fei L, Wang Y. microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB. IUBMB Life. 2020;72(7):1468–80.
Google Scholar
Collins SM. The intestinal microbiota in the irritable bowel syndrome. Int Rev Neurobiol. 2016;131:247–61.
Google Scholar
Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med 2017, 6(11).
Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. lancet Gastroenterol Hepatol. 2016;1(2):133–46.
Google Scholar
Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17–44.
Google Scholar
Yu LM, Zhao KJ, Wang SS, Wang X, Lu B. Corticotropin-releasing factor induces inflammatory cytokines via the NLRP6-inflammatory cytokine axis in a murine model of irritable bowel syndrome. J Dig Dis. 2019;20(3):143–51.
Google Scholar
Tasneem S, Liu B, Li B, Choudhary MI, Wang W. Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacol Res. 2019;139:126–40.
Google Scholar
Song X, Zhang Y, Dai E, Wang L, Du H. Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking. Int Immunopharmacol. 2020;80:106179.
Google Scholar
Yao P, Li Y, Yang Y, Yu S, Chen Y. Triptolide improves cognitive dysfunction in rats with vascular dementia by activating the SIRT1/PGC-1α signaling pathway. Neurochem Res. 2019;44(8):1977–85.
Google Scholar
Liu YC, Liu YL, Hsieh JY, Wang CH, Lin CL, Liu GY, Hung HC. Baicalein, 7,8-Dihydroxyflavone and myricetin as potent inhibitors of human ornithine decarboxylase. Nutrients 2020, 12(12).
Somani RR, Rai PR, Kandpile PS. Ornithine Decarboxylase Inhibition: a strategy to Combat various Diseases. Mini Rev Med Chem. 2018;18(12):1008–21.
Google Scholar
Yurdagul A Jr, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK, Rymond CC, Gerlach BD, Zheng Z, et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of Injury. Cell Metabol. 2020;31(3):518–533e510.
Google Scholar
Kim HI, Schultz CR, Buras AL, Friedman E, Fedorko A, Seamon L, Chandramouli GVR, Maxwell GL, Bachmann AS, Risinger JI. Ornithine decarboxylase as a therapeutic target for endometrial cancer. PLoS ONE. 2017;12(12):e0189044.
Google Scholar
Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4(10):781–92.
Google Scholar
Casero RA Jr, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discovery. 2007;6(5):373–90.
Google Scholar
Hardbower DM, Asim M, Luis PB, Singh K, Barry DP, Yang C, Steeves MA, Cleveland JL, Schneider C, Piazuelo MB, et al. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications. Proc Natl Acad Sci USA. 2017;114(5):E751–e760.
Google Scholar
